Literature DB >> 23547142

The immune response to pneumococcal polysaccharides 14 and 23F among elderly individuals consists predominantly of switched memory B cells.

David J Leggat1, Rebecca S Thompson, Noor M Khaskhely, Anita S Iyer, M A Julie Westerink.   

Abstract

The phenotype of B cells that respond to vaccination with the purified pneumococcal polysaccharide (PPS) has been a topic of debate. We have recently identified the phenotype of cells from healthy young volunteers as CD27(+)IgM(+) B cells. However, the PPS-responding B-cell population has not yet been identified in high-risk populations, such as elderly individuals. Previous studies have shown that elderly individuals have a lower percentage of immunoglobulin M memory B cells than healthy young adults. In this study, we directly characterized the phenotype of PPS-specific B cells before and after vaccination with PPS vaccine (PPV) in elderly adults, using fluorescently labeled PPS14 and PPS23F. In contrast to our observations in healthy young volunteers, the PPS-responding B-cell population consisted primarily of switched memory (CD27(+)IgM(-)) B cells. In concurrence with these findings, postvaccination immunoglobulin M concentrations were not significantly increased in this population, and the opsonophagocytic response was decreased, compared with that in young adults. These findings identify a significant shift in the phenotype of the B-cell population in response to PPV among elderly individuals.

Entities:  

Keywords:  23F; B cell; CD27; Pneumococcus; Streptococcus pneumoniae; elderly; flow cytometry; human; polysaccharide; vaccine

Mesh:

Substances:

Year:  2013        PMID: 23547142      PMCID: PMC3666141          DOI: 10.1093/infdis/jit139

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  38 in total

1.  Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly.

Authors:  U Sankilampi; P O Honkanen; A Bloigu; M Leinonen
Journal:  J Infect Dis       Date:  1997-10       Impact factor: 5.226

2.  Quantitation of blood lymphocytes secreting antibodies to pneumococcal polysaccharides after in vivo antigenic stimulation.

Authors:  C Heilmann; F K Pedersen
Journal:  Scand J Immunol       Date:  1986-02       Impact factor: 3.487

3.  Immaturity of the human splenic marginal zone in infancy. Possible contribution to the deficient infant immune response.

Authors:  W Timens; A Boes; T Rozeboom-Uiterwijk; S Poppema
Journal:  J Immunol       Date:  1989-11-15       Impact factor: 5.422

4.  Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study.

Authors:  M S Simberkoff; A P Cross; M Al-Ibrahim; A L Baltch; P J Geiseler; J Nadler; A S Richmond; R P Smith; G Schiffman; D S Shepard
Journal:  N Engl J Med       Date:  1986-11-20       Impact factor: 91.245

5.  Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency.

Authors:  Jeremy G Schenkein; Saeyoung Park; Moon H Nahm
Journal:  Vaccine       Date:  2008-08-13       Impact factor: 3.641

6.  The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

Authors:  E D Shapiro; A T Berg; R Austrian; D Schroeder; V Parcells; A Margolis; R K Adair; J D Clemens
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

7.  Immune response of elderly adults to pneumococcus: variation by age, sex, and functional impairment.

Authors:  K J Roghmann; P A Tabloski; D W Bentley; G Schiffman
Journal:  J Gerontol       Date:  1987-05

8.  Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease.

Authors:  Melanie Hart; Alan Steel; Sally A Clark; Graeme Moyle; Mark Nelson; Don C Henderson; Robert Wilson; Frances Gotch; Brian Gazzard; Peter Kelleher
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422

9.  Pneumococcal conjugate vaccine for adults: a new paradigm.

Authors:  Peter R Paradiso
Journal:  Clin Infect Dis       Date:  2012-04-11       Impact factor: 9.079

10.  Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen.

Authors:  Stephanie Kruetzmann; M Manuela Rosado; Holger Weber; Ulrich Germing; Olivier Tournilhac; Hans-Hartmut Peter; Reinhard Berner; Anke Peters; Thomas Boehm; Alessandro Plebani; Isabella Quinti; Rita Carsetti
Journal:  J Exp Med       Date:  2003-04-07       Impact factor: 14.307

View more
  23 in total

1.  No Benefit to Delaying Pneumococcal Polysaccharide Vaccination in HIV-Positive Adults.

Authors:  David J Leggat; Anita S Iyer; M A Julie Westerink
Journal:  J Infect Dis       Date:  2015-06-24       Impact factor: 5.226

2.  Polysaccharide-specific B cell responses to vaccination in humans.

Authors:  Ruth Mitchell; Dominic F Kelly; Andrew J Pollard; Johannes Trück
Journal:  Hum Vaccin Immunother       Date:  2014-03-14       Impact factor: 3.452

3.  Protease Inhibitors Do Not Affect Antibody Responses to Pneumococcal Vaccination.

Authors:  Indhira De La Rosa; Iona M Munjal; Maria Rodriguez-Barradas; Xiaoying Yu; Liise-Anne Pirofski; Daniel Mendoza
Journal:  Clin Vaccine Immunol       Date:  2016-06-06

Review 4.  Humoral immune responses to Streptococcus pneumoniae in the setting of HIV-1 infection.

Authors:  Lumin Zhang; Zihai Li; Zhuang Wan; Andrew Kilby; J Michael Kilby; Wei Jiang
Journal:  Vaccine       Date:  2015-06-30       Impact factor: 3.641

5.  Quantitative and Functional Antibody Responses to the 13-Valent Conjugate and/or 23-Valent Purified Polysaccharide Vaccine in Aging HIV-Infected Adults.

Authors:  Jennifer A Ohtola; Jessica L Saul-McBeth; Anita S Iyer; David J Leggat; Sadik A Khuder; Noor M Khaskhely; Ma Julie Westerink
Journal:  J AIDS Clin Res       Date:  2016-03-14

Review 6.  Variability in the immune system: of vaccine responses and immune states.

Authors:  Shai S Shen-Orr; David Furman
Journal:  Curr Opin Immunol       Date:  2013-08-13       Impact factor: 7.486

7.  Quantitative and Qualitative Antibody Responses to Immunization With the Pneumococcal Polysaccharide Vaccine in HIV-Infected Patients After Initiation of Antiretroviral Treatment: Results From a Randomized Clinical Trial.

Authors:  Maria C Rodriguez-Barradas; Jose A Serpa; Iona Munjal; Daniel Mendoza; Adriana M Rueda; Mahwish Mushtaq; Liise-Anne Pirofski
Journal:  J Infect Dis       Date:  2014-12-23       Impact factor: 5.226

8.  Race-related differences in functional antibody response to pneumococcal vaccination in HIV-infected individuals.

Authors:  Myroslawa Happe; Devadoss J Samuvel; Jennifer A Ohtola; Jeff E Korte; M A Julie Westerink
Journal:  Vaccine       Date:  2019-02-21       Impact factor: 3.641

9.  23-valent pneumococcal polysaccharide vaccine elicits hierarchical antibody and cellular responses in healthy and tuberculosis-cured elderly, and HIV-1-infected subjects.

Authors:  Huichang Huang; Xiaohua Qian; Rong Pan; Ling Shen; Shanshan Liang; Feifei Wang; Peng Zhang; Hongbo Shen; Zheng W Chen
Journal:  Clin Immunol       Date:  2018-05-09       Impact factor: 3.969

10.  Pneumococcal polysaccharide vaccination induces polysaccharide-specific B cells in adult peripheral blood expressing CD19⁺CD20⁺CD3⁻CD70⁻CD27⁺IgM⁺CD43⁺CD5⁺/⁻.

Authors:  David J Leggat; Noor M Khaskhely; Anita S Iyer; Jason Mosakowski; Rebecca S Thompson; John D Weinandy; M A Julie Westerink
Journal:  Vaccine       Date:  2013-08-01       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.